Loxo Oncology, Inc. 4
4 · Loxo Oncology, Inc. · Filed Aug 6, 2014
Insider Transaction Report
Form 4
Naider Avi Z.
Director
Transactions
- Conversion
Series B Convertible Preferred Stock
2014-08-05−13,518→ 0 totalExercise: $0.00→ Common Stock (13,518 underlying) - Conversion
Common Stock
2014-08-06+76,017→ 151,499 total - Purchase
Common Stock
2014-08-06$13.00/sh+3,846$49,998→ 155,345 total - Conversion
Series A Convertible Preferred Stock
2014-08-06−62,499→ 0 totalExercise: $0.00→ Common Stock (62,499 underlying)
Footnotes (2)
- [F1]In connection with the consummation of the Issuer's initial public offering on August 6, 2014, each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration. All shares of Common Stock issued upon conversion were aggregated.
- [F2]None.